- Home
- FORM vs KNSA Comparison
FORM vs KNSA Comparison
Compare FORM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORM
- KNSA
- Stock Information
- Founded
- FORM 1993
- KNSA 2015
- Country
- FORM United States
- KNSA United Kingdom
- Employees
- FORM N/A
- KNSA N/A
- Industry
- FORM Semiconductors
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- FORM Technology
- KNSA Health Care
- Exchange
- FORM Nasdaq
- KNSA Nasdaq
- Market Cap
- FORM 3.0B
- KNSA 2.6B
- IPO Year
- FORM N/A
- KNSA 2018
- Fundamental
- Price
- FORM $43.43
- KNSA $39.06
- Analyst Decision
- FORM Buy
- KNSA Strong Buy
- Analyst Count
- FORM 8
- KNSA 7
- Target Price
- FORM $40.86
- KNSA $46.86
- AVG Volume (30 Days)
- FORM 1.0M
- KNSA 458.1K
- Earning Date
- FORM 10-29-2025
- KNSA 10-28-2025
- Dividend Yield
- FORM N/A
- KNSA N/A
- EPS Growth
- FORM N/A
- KNSA N/A
- EPS
- FORM 0.57
- KNSA 0.07
- Revenue
- FORM $764,554,000.00
- KNSA $529,332,000.00
- Revenue This Year
- FORM $2.58
- KNSA $53.93
- Revenue Next Year
- FORM $7.33
- KNSA $25.06
- P/E Ratio
- FORM $75.95
- KNSA $602.30
- Revenue Growth
- FORM 8.30
- KNSA 56.18
- 52 Week Low
- FORM $22.58
- KNSA $17.82
- 52 Week High
- FORM $50.79
- KNSA $39.79
- Technical
- Relative Strength Index (RSI)
- FORM 63.82
- KNSA 61.74
- Support Level
- FORM $40.60
- KNSA $38.02
- Resistance Level
- FORM $44.35
- KNSA $39.45
- Average True Range (ATR)
- FORM 2.05
- KNSA 1.11
- MACD
- FORM -0.00
- KNSA -0.12
- Stochastic Oscillator
- FORM 85.50
- KNSA 81.07
About FORM FormFactor Inc. FormFactor Inc.
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.